NCT04676711View on ClinicalTrials.gov

A Study of GFH312 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

May 23, 2022

Study Completion Date

October 31, 2022

Conditions
ToxicityHealthy
Interventions
DRUG

GFH312

Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses

DRUG

Placebo

Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors
lead

GenFleet Therapeutics (Australia) Pty Ltd.

INDUSTRY